Cargando…
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
Multiple myeloma (MM) is a plasma-cell neoplasm that is treated with high-dose chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance. The presence of somatic mutations in the peripheral blood is termed clonal hematopoiesis of indeterminate potent...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293239/ https://www.ncbi.nlm.nih.gov/pubmed/32533060 http://dx.doi.org/10.1038/s41467-020-16805-5 |
| _version_ | 1783546259302252544 |
|---|---|
| author | Mouhieddine, Tarek H. Sperling, Adam S. Redd, Robert Park, Jihye Leventhal, Matthew Gibson, Christopher J. Manier, Salomon Nassar, Amin H. Capelletti, Marzia Huynh, Daisy Bustoros, Mark Sklavenitis-Pistofidis, Romanos Tahri, Sabrin Hornburg, Kalvis Dumke, Henry Itani, Muhieddine M. Boehner, Cody J. Liu, Chia-Jen AlDubayan, Saud H. Reardon, Brendan Van Allen, Eliezer M. Keats, Jonathan J. Stewart, Chip Mehr, Shaadi Auclair, Daniel Schlossman, Robert L. Munshi, Nikhil C. Anderson, Kenneth C. Steensma, David P. Laubach, Jacob P. Richardson, Paul G. Ritz, Jerome Ebert, Benjamin L. Soiffer, Robert J. Trippa, Lorenzo Getz, Gad Neuberg, Donna S. Ghobrial, Irene M. |
| author_facet | Mouhieddine, Tarek H. Sperling, Adam S. Redd, Robert Park, Jihye Leventhal, Matthew Gibson, Christopher J. Manier, Salomon Nassar, Amin H. Capelletti, Marzia Huynh, Daisy Bustoros, Mark Sklavenitis-Pistofidis, Romanos Tahri, Sabrin Hornburg, Kalvis Dumke, Henry Itani, Muhieddine M. Boehner, Cody J. Liu, Chia-Jen AlDubayan, Saud H. Reardon, Brendan Van Allen, Eliezer M. Keats, Jonathan J. Stewart, Chip Mehr, Shaadi Auclair, Daniel Schlossman, Robert L. Munshi, Nikhil C. Anderson, Kenneth C. Steensma, David P. Laubach, Jacob P. Richardson, Paul G. Ritz, Jerome Ebert, Benjamin L. Soiffer, Robert J. Trippa, Lorenzo Getz, Gad Neuberg, Donna S. Ghobrial, Irene M. |
| author_sort | Mouhieddine, Tarek H. |
| collection | PubMed |
| description | Multiple myeloma (MM) is a plasma-cell neoplasm that is treated with high-dose chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance. The presence of somatic mutations in the peripheral blood is termed clonal hematopoiesis of indeterminate potential (CHIP) and is associated with adverse outcomes. Targeted sequencing of the stem cell product from 629 MM patients treated by ASCT at the Dana-Farber Cancer Institute (2003–2011) detects CHIP in 136/629 patients (21.6%). The most commonly mutated genes are DNMT3A, TET2, TP53, ASXL1 and PPM1D. Twenty-one from fifty-six patients (3.3%) receiving first-line IMiD maintenance develop a therapy-related myeloid neoplasm (TMN). However, regardless of CHIP status, the use of IMiD maintenance associates with improved PFS and OS. In those not receiving IMiD maintenance, CHIP is associated with decreased overall survival (OS) (HR:1.34, p = 0.02) and progression free survival (PFS) (HR:1.45, p < 0.001) due to an increase in MM progression. |
| format | Online Article Text |
| id | pubmed-7293239 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72932392020-06-16 Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant Mouhieddine, Tarek H. Sperling, Adam S. Redd, Robert Park, Jihye Leventhal, Matthew Gibson, Christopher J. Manier, Salomon Nassar, Amin H. Capelletti, Marzia Huynh, Daisy Bustoros, Mark Sklavenitis-Pistofidis, Romanos Tahri, Sabrin Hornburg, Kalvis Dumke, Henry Itani, Muhieddine M. Boehner, Cody J. Liu, Chia-Jen AlDubayan, Saud H. Reardon, Brendan Van Allen, Eliezer M. Keats, Jonathan J. Stewart, Chip Mehr, Shaadi Auclair, Daniel Schlossman, Robert L. Munshi, Nikhil C. Anderson, Kenneth C. Steensma, David P. Laubach, Jacob P. Richardson, Paul G. Ritz, Jerome Ebert, Benjamin L. Soiffer, Robert J. Trippa, Lorenzo Getz, Gad Neuberg, Donna S. Ghobrial, Irene M. Nat Commun Article Multiple myeloma (MM) is a plasma-cell neoplasm that is treated with high-dose chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance. The presence of somatic mutations in the peripheral blood is termed clonal hematopoiesis of indeterminate potential (CHIP) and is associated with adverse outcomes. Targeted sequencing of the stem cell product from 629 MM patients treated by ASCT at the Dana-Farber Cancer Institute (2003–2011) detects CHIP in 136/629 patients (21.6%). The most commonly mutated genes are DNMT3A, TET2, TP53, ASXL1 and PPM1D. Twenty-one from fifty-six patients (3.3%) receiving first-line IMiD maintenance develop a therapy-related myeloid neoplasm (TMN). However, regardless of CHIP status, the use of IMiD maintenance associates with improved PFS and OS. In those not receiving IMiD maintenance, CHIP is associated with decreased overall survival (OS) (HR:1.34, p = 0.02) and progression free survival (PFS) (HR:1.45, p < 0.001) due to an increase in MM progression. Nature Publishing Group UK 2020-06-12 /pmc/articles/PMC7293239/ /pubmed/32533060 http://dx.doi.org/10.1038/s41467-020-16805-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Article Mouhieddine, Tarek H. Sperling, Adam S. Redd, Robert Park, Jihye Leventhal, Matthew Gibson, Christopher J. Manier, Salomon Nassar, Amin H. Capelletti, Marzia Huynh, Daisy Bustoros, Mark Sklavenitis-Pistofidis, Romanos Tahri, Sabrin Hornburg, Kalvis Dumke, Henry Itani, Muhieddine M. Boehner, Cody J. Liu, Chia-Jen AlDubayan, Saud H. Reardon, Brendan Van Allen, Eliezer M. Keats, Jonathan J. Stewart, Chip Mehr, Shaadi Auclair, Daniel Schlossman, Robert L. Munshi, Nikhil C. Anderson, Kenneth C. Steensma, David P. Laubach, Jacob P. Richardson, Paul G. Ritz, Jerome Ebert, Benjamin L. Soiffer, Robert J. Trippa, Lorenzo Getz, Gad Neuberg, Donna S. Ghobrial, Irene M. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant |
| title | Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant |
| title_full | Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant |
| title_fullStr | Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant |
| title_full_unstemmed | Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant |
| title_short | Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant |
| title_sort | clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293239/ https://www.ncbi.nlm.nih.gov/pubmed/32533060 http://dx.doi.org/10.1038/s41467-020-16805-5 |
| work_keys_str_mv | AT mouhieddinetarekh clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT sperlingadams clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT reddrobert clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT parkjihye clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT leventhalmatthew clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT gibsonchristopherj clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT maniersalomon clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT nassaraminh clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT capellettimarzia clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT huynhdaisy clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT bustorosmark clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT sklavenitispistofidisromanos clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT tahrisabrin clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT hornburgkalvis clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT dumkehenry clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT itanimuhieddinem clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT boehnercodyj clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT liuchiajen clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT aldubayansaudh clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT reardonbrendan clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT vanalleneliezerm clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT keatsjonathanj clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT stewartchip clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT mehrshaadi clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT auclairdaniel clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT schlossmanrobertl clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT munshinikhilc clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT andersonkennethc clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT steensmadavidp clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT laubachjacobp clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT richardsonpaulg clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT ritzjerome clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT ebertbenjaminl clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT soifferrobertj clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT trippalorenzo clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT getzgad clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT neubergdonnas clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant AT ghobrialirenem clonalhematopoiesisisassociatedwithadverseoutcomesinmultiplemyelomapatientsundergoingtransplant |